Thrombin inhibition profiles in healthy individuals and thrombophilic patients

Summary

Inhibition of thrombin by endogenous inhibitors plays a central role in the spatiotemporal control of clot formation. A failure to adequately inactivate thrombin such as in antithrombin deficiency generates a strong prothrombotic phenotype. To study if and to what extent delayed thrombin inactivation rates beyond antithrombin deficiency contribute to the prothrombotic phenotype we measured thrombin inhibition profiles in plasma samples obtained from 16 healthy individuals and 39 thrombophilic patients, including 17 patients diagnosed positive for anti-prothrombin/phospholipid antibodies. To test thrombin inhibition, thrombin was added to plasma, and endogenous thrombin inhibition stopped by addition of the reversible thrombin inhibitor argatroban. Subsequently, the amount of argatroban-complexed thrombin was measured using an oligonucleotide-based enzyme capture assay. In normal human plasma thrombin at concentrations up to 4 ng/ml (109 pM) became inactivated with an average half-life time of 56.4 ± 4.7 seconds (s). In antithrombin-deficient plasma the thrombin half-life was prolonged to 168.2 ± 14.9 s. Among the thrombophilic patients, only one with mild antithrombin deficiency showed impaired thrombin inactivation rates, whereas all other patients including the antiphospholipid positive patients showed thrombin inhibiting capacities within the normal range. We conclude that thrombin added to normal human plasma at subthreshold levels of ∼100 pM or below becomes inactivated with a half-life time below 1 minute. Antiphospholipid antibodies do not prolong thrombin half-life times, making it unlikely that delayed thrombin inactivation contributes to the thrombotic phenotype of the antiphospholipid syndrome. In contrast, plasma levels of antithrombin falling below 80% of normal markedly prolong the thrombin half-life.

Keywords

Thrombin - half-life time - inactivation - antithrombin - antiphospholipid syndrome

Both authors contributed equally to the study.

• References

• 1 Monroe DM, Hoffman M. What does it take to make the perfect clot?. Arterioscler Thromb Vasc Biol 2006; 26: 41-48.
• 2 Crawley JT, Zanardelli S, Chion CK. et al. The central role of thrombin in hemostasis. J Thromb Haemost 2007; 05 (Suppl. 01) 95-101.
• 3 Mann KG. Thrombin generation in hemorrhage control and vascular occlusion. Circulation 2011; 124: 225-235.
• 4 Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009; 108: 1433-1446.
• 5 Al Dieri R, Hemker CH. Thrombin generation in whole blood. Br J Haematol 2007; 139: 106-112.
• 6 Gomez K, McVey JH, Tuddenham E. Inhibition of coagulation by macromolecular complexes. Hematologica 2005; 90: 1570-1576.
• 7 Rau JC, Beaulieu LM, Huntington JA. et al. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 2007; 05 (Suppl. 01) 102-115.
• 8 Lambrianides A, Turner-Stokes T, Pericleous C. et al. Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in haemostasis. Arthritis Rheum 2011; 63: 3512-3521.
• 9 Kolev K, Lerant I, Skopal J. et al. Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with antithrombin antibody from a patient with antiphospholipid syndrome. Thromb Haemost 2005; 94: 82-87.
• 10 Hwang KK, Grossman JM, Visvanathan S. et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167: 7192-7198.
• 11 Hemker HC, Al Dieri R, De Smedt E. et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96: 553-561.
• 12 Castoldi E, Rosing J. Thrombin generation tests. Thrombosis Research 2011; 127 (Suppl. 03) S21-S25.
• 13 Müller J, Becher T, Braunstein J. et al. In vivo profiling of thrombin activity via supramolecular complexes. Angew Chem Int Ed Engl 2011; 50: 6075-6078.
• 14 Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229-1239.